MetaCap

Evolus (EOLS) vs Lyell Immunopharma (LYEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Evolus (EOLS) has outperformed Lyell Immunopharma (LYEL) over the past year, losing 4.8% versus a loss of 27.9%. Over five years, EOLS leads with a +14.4% price change compared with -92.6% for LYEL. Lyell Immunopharma is the larger company by market cap ($441.8 million vs $431.5 million), about 1.0 times the size, while Evolus is growing revenue faster (+11.6% vs -41.0%).

Evolus converts more of its revenue into profit, with a net margin of -17.4% versus -762355.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EOLS-4.82%LYEL-27.86%
+110%+21%-69%
Nov 21, 20251 yearNov 20, 2026
EOLS+2.19%LYEL-93.62%
+188%+39%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EOLS versus LYEL key metrics
MetricEOLSLYEL
Share price$6.52$13.80
Market cap$431.55M$441.82M
1-day change-6.86%+1.62%
YTD return-1.95%-55.17%
1-year return-4.82%-27.86%
5-year return+14.39%-92.59%
Forward P/E22.68—
EPS (TTM)$-0.48$-12.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$297.18M$36.00K
Revenue growth (YoY)+11.61%-40.98%
Net income (latest FY)$-51.64M$-274.45M
Gross margin66.33%—
Operating margin-10.99%-748344.44%
Net margin-17.38%-762355.56%
52-week high$9.31$45.00
52-week low$3.86$7.20
Distance from 52-week high-29.97%-69.33%
Analyst consensusstrong_buybuy
Avg. price target upside+136.20%+172.68%
Average volume925.77K174.76K
Shares outstanding66.19M32.02M
Employees365161
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EOLS has outperformed LYEL by 23.0 percentage points over the past year.
  • Evolus is more profitable, keeping -17.4 cents of every revenue dollar as net income versus -762355.6 cents for Lyell Immunopharma.
  • Evolus grew revenue faster in its latest fiscal year (+11.61% vs -40.98%).

About Evolus

EOLS stock →

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.

Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees

About Lyell Immunopharma

LYEL stock →

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

EOLS vs LYEL FAQ

Which is bigger, Evolus or Lyell Immunopharma?

Lyell Immunopharma (LYEL) is larger, with a market capitalization of $441.82M compared with $431.55M for Evolus (EOLS).

Which stock has performed better over the past year, EOLS or LYEL?

EOLS returned -4.82% over the past 12 months, compared with -27.86% for LYEL (price return, excluding dividends). Past performance does not predict future results.

Are Evolus and Lyell Immunopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons